Hytönen Jarkko P, Leppänen Olli, Taavitsainen Jouni, Korpisalo Petra, Laidinen Svetlana, Alitalo Kari, Wadström Jonas, Rissanen Tuomas T, Ylä-Herttuala Seppo
A.I. Virtanen Institute of Molecular Medicine, University of Eastern Finland, Kuopio, Finland.
Molecular/Cancer Biology Laboratory, Biomedicum Helsinki, Helsinki, Finland.
Vasc Biol. 2019 Jan 3;1(1):1-9. doi: 10.1530/VB-18-0001. eCollection 2019.
Prosthetic vascular grafts in humans characteristically lack confluent endothelialization regardless of the duration of implantation. Use of high-porosity grafts has been proposed as a way to induce endothelialization through transgraft capillarization, although early experiments failed to show increased healing in man.
We hypothesized that transduction of tissues around the prosthetic conduit with vectors encoding VEGF receptor-2 (VEGFR2) ligands would augment transinterstitial capillarization and induce luminal endothelialization of high-porosity ePTFE grafts.
Fifty-two NZW rabbits received 87 ePTFE uni- or bilateral end-to-end interposition grafts in carotid arteries. Rabbits were randomized to local therapy with adenoviruses encoding AdVEGF-A165, AdVEGF-A109 or control AdLacZ and analyzed at 6 and 28 days after surgery by contrast-enhanced ultrasound and histology.
AdVEGF-A165 and AdVEGF-A109 dramatically increased perfusion in perigraft tissues at 6 days (14.2 ± 3.6 or 16.7 ± 2.6-fold increases, < 0.05 and < 0.01). At 28 days, the effect was no longer significantly higher than baseline. At 6 days, no luminal endothelialization was observed in any of the groups. At 28 days, AdVEGF-A109- and AdVEGF-A165-treated animals showed enhanced ingrowth of transinterstitial capillaries (66.0 ± 13.7% and 77.4 ± 15.7% of graft thickness vs 44.7 ± 24.4% in controls, < 0.05) and improved luminal endothelialization (11.2 ± 26.3% and 11.4 ± 22.2%, AdVEGF-A109 and AdVEGF-A165 vs 0% in controls, < 0.05). No increased stenosis was observed in the treatment groups as compared to LacZ controls.
This study suggests that transient local overexpression of VEGFR2 ligands in the peri-implant tissues at the time of graft implantation is a novel strategy to increase endothelialization of high-porosity ePTFE vascular grafts and improve the patency of small-diameter vascular prostheses.
无论植入时间长短,人体中的人工血管移植物通常都缺乏融合的内皮化。尽管早期实验未能显示在人体中愈合增加,但使用高孔隙率移植物已被提议作为一种通过移植物毛细血管化诱导内皮化的方法。
我们假设用编码血管内皮生长因子受体-2(VEGFR2)配体的载体转导人工血管周围组织会增强跨间质毛细血管化,并诱导高孔隙率ePTFE移植物的管腔内皮化。
52只新西兰白兔在颈动脉接受了87个ePTFE单侧或双侧端对端插入移植物。兔子被随机分为用编码AdVEGF-A165、AdVEGF-A109的腺病毒或对照AdLacZ进行局部治疗,并在术后6天和28天通过超声造影和组织学进行分析。
AdVEGF-A165和AdVEGF-A109在6天时显著增加了移植物周围组织的灌注(分别增加14.2±3.6倍或16.7±2.6倍,P<0.05和P<0.01)。在28天时,这种效应不再显著高于基线。在6天时,任何组均未观察到管腔内皮化。在28天时,接受AdVEGF-A109和AdVEGF-A165治疗的动物显示跨间质毛细血管向内生长增强(分别占移植物厚度的66.0±13.7%和77.4±15.7%,而对照组为44.7±24.4%,P<0.05),管腔内皮化改善(AdVEGF-A109和AdVEGF-A165组分别为11.2±26.3%和11.4±22.2%,对照组为0%,P<0.05)。与LacZ对照组相比,治疗组未观察到狭窄增加。
本研究表明,在移植物植入时在植入周围组织中短暂局部过表达VEGFR2配体是一种增加高孔隙率ePTFE血管移植物内皮化并改善小直径血管假体通畅性的新策略。